A recent study suggests that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who stop traditional diet and exercise programs.
Research printed in a major medical journal demonstrates that while overweight people frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be cognizant of the risk of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass in about a year and a half.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that people who lose weight through lifestyle changes alone generally experience a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Experts believe the mechanism of the drugs accounts for the amplified weight return.
The injections copy a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels far above than normal might result in the body to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating a significant risk."
An Ongoing Condition?
The NHS suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who note that the findings "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
User Testimonies
People who have come off the jabs explain a powerful return of cravings.
"It felt as if a trigger that goes on and you become extremely hungry," recalled an individual.
This challenge is compounded if individuals have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Interest
Figures show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among females than males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are potent tools for weight loss, they are not a permanent solution and long-term success hinges on integrated behavioural support.
